FDA Grants Accelerated Approval for Liso-Cel for R/R Follicular Lymphoma

FDA has given accelerated approval for lisocabtagene maraleucel (liso-cel; Breyanzi) for patients with relapsed or refractory (R/R) follicular lymphoma.

Related Keywords

San Diego ,California ,United States ,American ,Meghan Gutierrez ,Bristol Myers Squibb ,Marial Palomba ,Follicular Lymphoma Foundation ,Transcend ,American Society Of Hematology ,Memorial Sloan Kettering Cancer Center ,Lymphoma Research Foundation ,Drug Administration ,Independent Review ,Risk Evaluation ,Mitigation Strategy ,Myers Squibb ,Cell Therapy Breyanzi Approved ,Refractory Follicular ,Bristol Myers ,Follicular Lymphoma ,Accessed May ,American Journal ,